Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation Leukemia (2004) Several variables have been previously identified as adverse risk factors for survival after HLA-identical sibling donor allogeneic stem cell transplantation (SCT). Indeed, advanced phase of disease is associated with increased relapse rate and death due to leukemia progression. On the other hand, factors influencing the incidence and severity of graft-versus-host disease (GvHD), such as sex mismatch (female donor and male recipient), older recipient age or positive CMV serology, are related to an increased transplant-related mortality. 1, 2 However, it is sometimes difficult to know the real impact of these risk factors on transplant outcome when considering a single patient, because favorable and adverse conditions may be present at the same time. In this work, we present a clinical score for predicting the survival of allogeneic SCT from HLA-identical sibling donors for myeloid malignancies on the basis of the evaluation and grading of risk factors available pretransplant.
We retrospectively analysed the pretransplant data and the clinical post-transplant outcome for 319 adult patients diagnosed of acute myeloid leukemia (AML) (n ¼ 150) or CML (n ¼ 169) who received an allogeneic SCT from an HLAidentical sibling donor from 1991 to 2002, performed in 14 centers. Patients with AML were assigned to the following FAB groups: M0: 3%; M1: 15%; M2: 24%; M3: 6%; M4: 25%; M5: 18%; M6: 3%; M7: 1%; post-MDS: 5%. The median follow-up for living patients was 2.8 years (range: 3 months-13 years). All the patients were older than 15 years and conditioned with myeloablative regimens.
Patients with AML beyond first complete remission and CML beyond first chronic phase were considered as with an advanced phase of disease. We considered sex mismatch as a female donor and a male recipient. GvHD was diagnosed and classified according to the Seattle's criteria. Transplant-related mortality (TRM) was defined as a death without disease relapse.
Univariate analysis for overall survival (OS) and disease-free survival (DFS), as well as the actuarial probabilities for grades III-IV acute GvHD, TRM and relapse were calculated by the Kaplan and Meier method. Comparison of curves was performed using the log-rank test. Multivariate analysis for OS was performed using the stepwise proportional hazard regression model.
The actuarial OS at 8 years was 59.2% for the whole cohort of patients. The multivariate analysis detected only three independent risk factors for poor survival: Age beyond 30 years (P ¼ 0.003, OR: 2.40; 95% CI: 1.34-4.30), advanced phase of disease (Po0.001, OR: 3.03; 95% CI: 1.92-4.78) and female donor for a male recipient (P ¼ 0.023, OR: 1.71; 95% CI: 1.07-2.74). Based on the results obtained in the multivariate analysis, patients were divided in four groups (or scores) depending on the following criteria: score 1: no risk factors (age o30 years, early phase of disease and absence of sex mismatch), 58 cases; score 2: early phase of disease with 1 or 2 risk factors (age 430 years7sex mismatch), 182 cases; score 3: advanced disease7age beyond 30 years or sex mismatch, 54 cases; and score 4: all three risk factors, 22 cases. Figure 1 shows the actuarial OS and DFS for each score. The actuarial OS was 94.2, 59.1, 45.7 and 8.3% for patients with scores 1-4, respectively. These differences were statistically significant (score 1 vs score 2: Po0.001; score 2 vs score 3: P ¼ 0.001; score 3 vs score 4: P ¼ 0.010). Actuarial DFS was 72.9, 51.6, 29.9 and 0% for each group. The comparison between each score was also statistically significant (score 1 vs score 2: P ¼ 0.004; score 2 vs score 3: Po0.001; score 3 vs score 4: P ¼ 0.063). When considering the TRM probability, there was a significant increase when comparing patients with score 1 (1.8%) and score 2 (19.5%) (P ¼ 0.002) and patients with score 3 (14%) and score 4 (75.7%) (Po0.001). Actuarial probability of developing grades III-IV acute GvHD was 10.6, 17.4, 22.8 and 33.7% for scores 1-4, respectively. The relapse rate for each score was 21.3, 34.9, 61.1 and 100%. Figure 2 shows the actuarial curves for OS and DFS separately for patients with AML or CML. The differences in OS between scores 1-4 becomes more evident in AML patients: 91.7, 61, 39.3 and 8.3% for scores 1-4 (score 1 vs score 2: P ¼ 0.003; score 2 vs score 3: P ¼ 0.016; score 3 vs score 4: P ¼ 0.003). DFS was also clearly influenced by the score in AML patients: 80.7, 56.3, 27.3 and 7.1% for scores 1-4 respectively.
We have identified two previously described risk factors for acute GvHD (sex mismatch and patient older than 30 years) 1,2 as independent risk factors for OS and DFS, increasing the risk of transplant-related death. Older age of the patient is also associated to an increased number of toxic deaths due to the conditioning regimen. The advanced phase of the disease is the third identified risk factor associated with a lower survival. Obviously, this is due Correspondence to the higher incidence of relapse in these patients. We therefore developed a scoring system to predict the outcome of the allogeneic transplantation for a given patient, which may be useful to offer to the patient a realistic expected survival after SCT. This approach has been used before to assess the risk of hematologic malignancies, such as non-Hodgkin's lymphoma.
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The Chronic Leukemia Working Party of the EBMT published a similar scoring approach for patients with CML receiving a stem cell donor. 4 They identified the same three pretransplant risk factors (disease stage, age of the patient and sex combination), but they added other two variables: donor type (related or unrelated donor transplant) and time from diagnosis to transplantation (before or after 12 months), identifying seven groups, with an OS of 72, 70, 62, 48, 40, 18 and 22% for patients with score 0-6, respectively. More recently, the Acute Leukemia Working Party of the EBMT published a similar experience when considering patients with acute lymphoblastic leukemia transplanted from an HLA-identical sibling donor.
5 For these patients, three risk factors were considered: patient's age 435 years old, first remission achievement with one or more induction courses, and the male recipient/female donor sex combination.
Our work is the first clinical observation applying a prognostic score to identify patients with AML who benefit most from allogeneic hematopoietic stem cell transplantation.
Obviously, patients in advanced phase of the disease have a higher risk of death. However, OS may improve if we select an HLA-identical sibling donor without sex mismatch, because patients with score 3 have a chance of about 45% to be cured after allogeneic SCT, whereas survival for those with score 4 is under 10%. It is worth mentioning the absence of statistically significant differences between score 2 and 3 on OS for patients with CML. This effect may be due to the better control of CML relapses after allogeneic SCT. 6 This grading score system allows the identification of four risk groups for patients with AML receiving an allogeneic SCT from an HLA-identical sibling donor based on pre-SCT variables easily available. This score could be used to improve the results of the poor-prognosis scores with innovative clinical trials. However, the main benefit of this classification is the possibility to offer a realistic percentage of success to the patient before the starting of the procedure, an information that is essential when discussing the transplant risk for the patient's informed consent. Patients with disseminated 'low-grade' or 'indolent' lymphoproliferative disorders such as follicular lymphoma and chronic lymphocytic leukaemia (CLL) remain incurable with currently available therapies, although temporary disease control can usually be obtained.
High-dose therapy with autologous stem cell rescue is an increasingly applied treatment for younger patients (o65 years). In patients with recurrent chemotherapy-sensitive low-grade non-Hodgkin's lymphoma (NHL), or CLL, high rates of complete remission and moderate rates of durable disease control can be attained.
For an autograft to be successful, a minimum number of stem cells must be obtained from a mobilization procedure, to ensure an acceptable rate of haemopoietic recovery and a low rate of graft failure. Patients with lymphoid malignancies, particularly those with 'low-grade' histology, have a higher rate of collection failure. 1 Many of these patients may have received multiple prior courses of potentially myelotoxic therapy. In a number of studies of this patient group, prior treatment with the purine analogue fludarabine has been associated with impaired mobilization. [2] [3] [4] [5] Ketterer et al 2 examined 200 patients with lymphoid malignancies and identified prior exposure to fludarabine as the most significant predictor of a sub-optimal stem cell collection (P ¼ 0.0008).
Given that fludarabine is a potent cytotoxic agent in both initial and salvage therapy of patients with lymphoproliferative disorders and is becoming more widely used in this setting, the problem of impaired stem cell mobilization may become an increasingly frequent clinical issue. Only one previous study 4 has specifically examined the factors contributing to poor stem cell yield in fludarabine-exposed patients, and was restricted to patients with CLL. We therefore analysed our own experience with peripheral blood stem cell (PBSC) mobilization in patients who had previously received fludarabine therapy, in order to identify factors associated with successful mobilization.
All patients from two centres who had received fludarabine at any time for treatment of an 'indolent' lymphoproliferative disorder, and subsequently had an attempt at stem cell mobilization between January 1996 and November 2002, were included in the study. Patients with follicular grade III or largecell lymphoma were excluded, but those with mantle cell lymphoma were included (n ¼ 2).
Data on a number of variables that may affect the ability to collect PBSC were collected. These included patient age, gender and ECOG performance status, histologic diagnosis, total dose of fludarabine received, response to fludarabine, time between the last dose of fludarabine and the mobilization procedure, and the nature of the fludarabine-containing regimen (fludarabine alone or combination therapy with other potentially myelotoxic agents). Data on prior radiotherapy were also collected, with radiation-related myelotoxicity considered possible when a significant proportion of bone marrow was included in the radiation field. Bone marrow reserve was indirectly assessed by bone marrow involvement and full blood count parameters at the time of mobilization. The impact of additional potentially myelotoxic chemotherapy apart from fludarabine was also considered, by allocating a 'toxicity score' for prior chemotherapy based on a published score. 6 Each drug given was allocated a number between 0 (nonmyelotoxic, eg prednisolone) and 4 (highly myelotoxic, eg melphalan), and this number was multiplied by the total number of drug cycles administered. One month of continuous chlorambucil was designated one 'cycle'. The 22 regimens for which the cycle number was unknown were considered to have had four cycles (the median number of cycles overall). Toxicity scores for all nonfludarabine chemotherapeutic agents were added to give a total score.
Peripheral blood (PB) CD34 þ count determined using threeparameter flow cytometry was used to determine the timing of commencement of stem cell harvesting. A threshold of 2 Â 10 6 /l CD34 þ cells was deemed adequate. PB CD34 þ count was performed on a daily basis until harvesting was complete. Daily leukaphereses were performed until a total of 42 Â 10 6 /kg CD34 þ cells were collected, or until a declining PB CD34 þ count indicated that further procedures were unlikely to be useful. For 12 of 54 mobilization attempts, the threshold PB CD34 þ count was not reached, and thus leukapheresis was never commenced.
